New drug targets Hard-to-Treat cancers with RAS mutations
NCT ID NCT07435038
First seen Mar 09, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study tests a new drug, BPI-572270, in 120 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The goal is to see if the drug is safe and can shrink tumors. Participants must have already tried standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.